Join
Live feed
·
PRReleasevia Quantisnow
Voyager Therapeutics Inc. logo

Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026

ByQuantisnow·Wall Street's wire, on your screen.
VYGR· Voyager Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VYGR (Voyager Therapeutics Inc.) and more on Quantisnow.